Artificial intelligence-based measurements of PET/CT imaging biomarkers are associated with disease-specific survival of high-risk prostate cancer patients.
Eirini PolymeriHenrik KjölhedeOlof EnqvistJohannes UlénMads H PoulsenJane Angel SimonsenPablo BorrelliElin TrägårdhÅse A JohnssonPoul Flemming Høilund-CarlsenLars EdenbrandtPublished in: Scandinavian journal of urology (2021)
AI-based assessments of total tumour volume and lesion uptake were significantly associated with disease-specific survival in this patient cohort, whereas SUVmax and Gleason scores were not. The AI-based approach appears well-suited for clinically relevant patient stratification and monitoring of individual therapy.
Keyphrases
- artificial intelligence
- prostate cancer
- pet ct
- machine learning
- big data
- deep learning
- end stage renal disease
- radical prostatectomy
- case report
- ejection fraction
- newly diagnosed
- chronic kidney disease
- high resolution
- peritoneal dialysis
- positron emission tomography
- free survival
- stem cells
- patient reported outcomes
- photodynamic therapy
- smoking cessation